ERBB2 and breast carcinoma: Moreover, entinostat has been found to enhance the anti‐tumour efficacy in combination with HER2‐targeted agents, such as lapatinib and trastuzumab in patients with HER2‐overexpressing breast cancer cells that are resistant to trastuzumab‐based treatment [36].